Editorial |
From the Departments of Pathology and Cellular & Molecular Biology, Baylor College of Medicine, Houston, Tex.
Correspondence to Mark W. Majesky, PhD, Center for Cardiovascular Development, Department of Pathology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030. E-mail mmajesky{at}bcm.tmc.edu
Key Words: embryo autonomous growth neointima proliferation
| Introduction |
|---|
|
|
|---|
| Autonomous Growth Phenotype |
|---|
|
|
|---|
20% per day at e19 to birth. The first surprise
came when e17 aortic SMCs placed in cell culture were found to
proliferate at high rates (up to 40% per day) in defined medium
entirely devoid of exogenous growth factors. Comparable cultures of
adult aortic SMCs became growth arrested and failed to replicate under
identical conditions. The ability of embryonic SMCs (eSMCs) to
proliferate in the complete absence of whole blood serum or
plasma-derived serum supplements was a stable property independent of
passage number or population doublings.2 Autonomously
replicating eSMCs failed to secrete detectable mitogenic
activity into conditioned medium and were mitogenically
unresponsive to a variety of known SMC growth factors, including
platelet-derived growth factor (PDGF), fibroblast growth factor-2,
epidermal growth factor, or 10% calf serum. Taken together, these
results raised the possibility of a unique mechanism of SMC growth
control, one that seemed to be self-regulated and uncoupled from a
dependence on exogenous growth factors. The capacity for self-driven
SMC replication was lost by e20, correlating in time with a large drop
in BrdU-labeling index values in fetal rat aorta in vivo. These early
studies suggested that the high SMC replication rates observed in
embryonic rat aorta in vivo are driven by mechanisms intrinsic to eSMCs
and that developmentally timed loss of this phenotype results
in the acquisition of proliferative quiescence during normal vascular
development. Subsequent work showed that an autonomous growth phenotype is reexpressed in adult rat carotid SMCs during neointimal formation after balloon injury.3 As obtained from the carotid artery wall 7 days after injury, autonomously replicating neo7 SMCs in vitro are epithelioid in shape and proliferate in serum-free medium at rates comparable to those exhibited by e17 SMCs. As observed for eSMCs, adult neo7 SMCs also failed to secrete detectable mitogenic activity into conditioned medium.3 Furthermore, direct coculture of neo7 SMCs with mitogen-dependent adult aortic SMCs failed to stimulate DNA synthesis in the target aortic SMCs.3 The autonomous growth behavior of SMCs from injured carotid arteries was a transient property that could no longer be observed in cells isolated from vessels at 21 and 28 days after balloon injury. These findings were consistent with a large body of literature suggesting that adult rat carotid SMCs reexpress a developmental sequence during neointimal formation after arterial injury.
| Heterokaryon Analysis |
|---|
|
|
|---|
| Cloning and Analysis of Emb Genes |
|---|
|
|
|---|
Expression data alone are often misinterpreted as evidence for a
functional role of a gene product in the tissues and cell types
where it is expressed. Loss-of-function experiments are required to
critically test for biological activity. Weiser-Evans et
al1 added sense and antisense emb8:EGAP
oligodeoxynucleotides (ODN) to eSMCs, neo7 SMCs, and
mitogen-dependent adult SMC cultures to determine if emb8:EGAP plays a
functional role in autonomous SMC growth. The results showed that
antisense ODN (5 µmol/L) reduced BrdU-labeling index values in
serum-free medium by 57% for neo7 SMCs and by 20% for eSMCs but had
no effect on BrdU index values for mitogen-dependent adult SMCs
stimulated with 10% whole blood serum. Sense ODN had no effect, and
neutralizing antibodies to interferon-
did not reverse growth
inhibition by antisense ODN. Lack of more substantial inhibition of
autonomous SMC growth by antisense emb8:EGAP ODN may indicate that
strategies to inhibit multiple emb genes at the same time will be
required to see greater inhibition. These data offer support, although
not proof, that emb8:EGAP may play an important functional role in
conferring autonomous growth potential on vascular SMCs in which it is
expressed. Critical next steps will be to verify that emb8:EGAP
antisense ODN reduces target RNA and emb8:EGAP protein levels in cells
whose growth is inhibited; determine if forced expression of emb8:EGAP
in mitogen-dependent SMCs converts them to a mitogen-independent growth
phenotype; characterize emb gene transcriptional regulation
and, in particular, whether emb genes exhibit positive autoregulation;
determine what the adult autonomous growth suppressor activity is; and
make germ-line mutations in emb8:EGAP in mice to assess their effects
on embryonic SMC replication and vascular development in vivo.
| Summary and Implications |
|---|
|
|
|---|
In summary, it is now apparent that SMC diversity is an important feature of the structure and function of normal arteries. This diversity extends to the level of SMC growth control, but the number of distinct growth phenotypes and the control of their expression in the vessel wall remain unclear. The cloning of SMC emb genes by Weiser-Evans et al1 provides an important new set of tools to reexamine these questions and additionally explore the implications of autonomous growth potential for SMC growth control in the intact artery wall.
| Footnotes |
|---|
| References |
|---|
|
|
|---|
2.
Cook C, Weiser M, Schwartz P, Jones C, Majack R.
Developmentally timed expression of an embryonic growth
phenotype in vascular smooth muscle cells. Circ
Res. 1994;74:189196.
3. Weiser-Evans M, Quinn B, Burkard M, Stenmark K. Transient reexpression of an embryonic autonomous growth phenotype by adult carotid artery smooth muscle cells after vascular injury. J Cell Physiol. 2000;182:1223.[Medline] [Order article via Infotrieve]
4. Majack R. Extinction of autonomous growth potential in embryonic: adult vascular smooth muscle cell heterokaryons. J Clin Invest. 1995;95:464468.
5.
Clegg C, Hauschka S. Heterokaryon analysis of
muscle differentiation: regulation of the postmitotic state.
J Cell Biol. 1987;105:937947.
6. Schwartz S, Foy L, Bowen-Pope D, Ross R. Derivation and properties of platelet-derived growth factor-independent rat smooth muscle cells. Am J Pathol. 1990;136:14171428.[Abstract]
7.
Walker L, Bowen-Pope D, Ross R, Reidy M.
Production of platelet-derived growth factor-like molecules
by cultured arterial smooth muscle cells accompanies
proliferation after arterial injury. Proc Natl Acad
Sci U S A. 1986;83:73117315.
8.
Gordon D, Mohai L, Schwartz S. Induction of polyploidy
in cultures of neonatal rat aortic smooth muscle cells. Circ
Res. 1986;59:633644.
9.
Majesky M, Benditt E, Schwartz S. Expression and
developmental control of platelet-derived growth factor A-chain and
B-chain/sis genes in rat aortic smooth muscle cells. Proc Natl
Acad Sci U S A. 1988;85:15241528.
10.
Bochaton-Piallat M-L, Ropraz P, Gabbiani F, Gabbiani G.
Phenotypic heterogeneity of rat arterial
smooth muscle cell clones: implications for the development of
experimental intimal thickening. Arterioscler Thromb Vasc
Biol. 1996;16:815820.
11.
Frid M, Alsashev A, Nemenoff R, Higashito R, Westcott
J, Stenmark K. Subendothelial cells from normal bovine
arteries exhibit autonomous growth and constitutively activated
intracellular signaling. Arterioscler Thromb Vasc Biol. 1999;19:28842893.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |